These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15560755)

  • 1. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
    Grassberger M; Steinhoff M; Schneider D; Luger TA
    Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
    Stuetz A; Grassberger M; Meingassner JG
    Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P; Ellis CN; Girolomoni G
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
    Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
    J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
    Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG
    Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro.
    Kalthoff FS; Winiski A; Fichtinger P; Schwendinger B; Wang S; Weishaeupl C; Stuetz A
    Int Arch Allergy Immunol; 2007; 142(3):255-64. PubMed ID: 17114891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
    Ständer S; Ständer H; Seeliger S; Luger TA; Steinhoff M
    Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function.
    Krummen MB; Varga G; Steinert M; Stuetz A; Luger TA; Grabbe S
    Exp Dermatol; 2006 Jan; 15(1):43-50. PubMed ID: 16364030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
    Hebert AA; Warken KA; Cherill R
    Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimecrolimus--a safe and effective local immunomodulator in the treatment of inflammatory skin diseases.
    Lipozencić J
    Acta Dermatovenerol Croat; 2005; 13(1):63-9. PubMed ID: 15788149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
    Goldstein AT; Thaçi D; Luger T
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.
    Meingassner JG; Aschauer H; Stuetz A; Billich A
    Exp Dermatol; 2005 Oct; 14(10):752-7. PubMed ID: 16176283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.
    Simon D; Vassina E; Yousefi S; Braathen LR; Simon HU
    Allergy; 2005 Jul; 60(7):944-51. PubMed ID: 15932386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
    Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
    Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development and pre-clinical aspects of pimecrolimus].
    Stütz A; Grassberger M; Meingassner JG
    Hautarzt; 2003 May; 54(5):405-12. PubMed ID: 12719859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.
    Bornhövd E; Burgdorf WH; Wollenberg A
    J Am Acad Dermatol; 2001 Nov; 45(5):736-43. PubMed ID: 11606925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimecrolimus 1% cream (Elidel) for atopic dermatitis.
    Bernard LA; Bergman JN; Eichenfield LF
    Skin Therapy Lett; 2002 Apr; 7(4):1-3. PubMed ID: 12097994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical pimecrolimus for skin disease other than atopic dermatitis.
    Wollina U; Hansel G; Koch A; Abdel-Naser MB
    Expert Opin Pharmacother; 2006 Oct; 7(14):1967-75. PubMed ID: 17020422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
    Werfel T
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.